Recent developments include positive Phase 1 data for RLYB116, a reverse stock split to regain Nasdaq compliance, and ongoing merger activities with Candid. The company has discontinued certain programs and continues to wind down operations ahead of the merger.

• Rallybio reported positive Phase 1 clinical trial data for RLYB116, demonstrating improved tolerability and complete inhibition of terminal complement, supporting its potential as a best-in-class therapeutic [N3].
• The company announced a 1-for-8 reverse stock split in early 2026 to regain Nasdaq compliance, which impacted its stock price [N4].
• Rallybio entered into a merger agreement with Candid in March 2026, including a concurrent financing of approximately $505.5 million to support the combined company [S1].
• The company has discontinued development of RLYB212 and ended its pregnancy-related rare disease program in 2025, reflecting pipeline prioritization [N5].
• Rallybio continues to wind down general and administrative operations not needed post-merger while maintaining limited R&D to advance key programs for contingent value rights [S1].

Rallybio's lead candidate RLYB116 offers a differentiated approach to complement-mediated diseases with potential patient-friendly subcutaneous administration and less frequent dosing, supported by positive Phase 1 data. The company's manufacturing process using E. coli expression may reduce costs compared to traditional antibodies. Strategic collaborations and a merger with Candid could provide enhanced resources and pipeline diversification. If clinical development progresses successfully, RLYB116 could address significant unmet needs in diseases like PTR and APS, potentially transforming treatment paradigms.

Rallybio faces risks including the uncertainty of completing the merger with Candid, which involves significant ownership dilution and operational restrictions. The company has no approved products and reported net losses with no revenue, reflecting typical clinical-stage biotech financial challenges. Development discontinuations of programs like RLYB212 and winding down of operations indicate pipeline risks. The small workforce and reliance on limited R&D may constrain execution. Competition from established therapies and regulatory hurdles add to development risks. The merger and related contingencies introduce additional uncertainties affecting shareholder value.

Rallybio's moat is anchored in its specialized focus on rare and severe diseases involving complement dysregulation and iron overload, leveraging proprietary engineered protein therapeutics such as RLYB116 with potential advantages in administration route, dosing frequency, and manufacturing efficiency. The company's leadership team has extensive biopharma experience, including prior development of approved C5 inhibitors. Strategic collaborations with AI-driven drug discovery and antibody discovery firms enhance its innovation capabilities. However, as a clinical-stage company without approved products, its moat is contingent on successful clinical development and regulatory approval, with competition from established antibody therapies and other biotech firms in rare disease spaces.

• Merger Completion Risks: The proposed merger with Candid is subject to numerous conditions and uncertainties, including potential delays, failure to satisfy closing conditions, and litigation risks that could adversely affect Rallybio's business and stock price.
• Ownership Dilution and Reduced Influence: Post-merger, Rallybio's existing stockholders will experience significant dilution, owning a minority stake with reduced voting power and influence over the combined company's management and strategic direction.
• Operational Restrictions Pre-Merger: The merger agreement imposes customary restrictions on Rallybio's business conduct prior to closing, potentially limiting its ability to pursue other transactions or operate freely.
• Small Workforce and Wind-Down Activities: As of September 30, 2026, Rallybio had only six full-time employees, reflecting wind-down of general operations, which may impact its ability to maintain R&D momentum and fulfill reporting obligations.
• Clinical and Regulatory Risks: Rallybio's lead candidates are in early clinical or preclinical stages with inherent risks of clinical trial failure, regulatory delays, or inability to achieve market approval.

• Rallybio Corp is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases, particularly complement-mediated disorders and diseases of iron overload.
• The lead product candidate is RLYB116, a once-weekly subcutaneous inhibitor of complement component 5 (C5), designed as an Affibody molecule linked to an albumin binding domain to extend half-life and improve patient convenience.
• RLYB116 targets diseases caused by complement dysregulation such as platelet transfusion refractoriness (PTR) and antiphospholipid syndrome (APS), aiming to provide a more accessible and patient-friendly treatment compared to existing antibody-based C5 inhibitors.
• RLYB116 has completed two Phase 1 clinical trials demonstrating improved tolerability and complete, sustained inhibition of terminal complement, supporting its potential as a best-in-class therapeutic.
• RLYB332 is a long-acting monoclonal antibody targeting matriptase-2 (MTP-2) for diseases of iron overload, currently in preclinical development with favorable pharmacodynamic data presented in 2024.
• Rallybio has strategic collaborations including a joint venture with Exscientia (now part of Recursion) for AI-driven drug discovery and a multi-year alliance with AbCellera for antibody therapeutics in rare diseases.
• In March 2026, Rallybio entered into a merger agreement with Candid, a clinical-stage biotech focused on T-cell engager therapeutics for autoimmune diseases, with a concurrent financing of approximately $505.5 million.
• Post-merger, Candid equityholders are expected to own the majority of the combined company, with Rallybio equityholders owning a minority stake; the merger includes contingent value rights (CVRs) for holders of Rallybio securities to receive proceeds from disposition of legacy assets.
• Rallybio has been winding down general and administrative operations not needed post-merger and maintaining limited R&D to advance programs for CVR value maximization.
• Financial snapshot as of September 30, 2026, shows cash and equivalents of $90.7 million, current assets of $94.8 million, current liabilities of $3.3 million, resulting in a strong current ratio of 28.87 and cash ratio of 27.63.
• The company reported zero revenue and a net loss of $2.7 million for the quarter ending September 30, 2026, with basic and diluted EPS of -$0.48 per share.
• Rallybio implemented a 1-for-8 reverse stock split in early 2026 to regain Nasdaq compliance.
• The company has discontinued development of certain programs including RLYB212 and ended a pregnancy-related rare disease program in 2025.
• Rallybio received positive Phase 1 data for RLYB116 in early 2026 and has ongoing clinical trial applications for RLYB212 in pregnant women with FNAIT approved in late 2024.
• The company has received milestone and upfront payments totaling $20 million from the sale of its interest in an ENPP1 inhibitor program to Recursion in 2025.
• Rallybio's management and board face risks related to the merger completion, including potential delays, failure to realize merger benefits, employee retention challenges, and litigation risks.
• The merger agreement includes customary restrictions on business conduct prior to closing, which may affect operations.
• The combined company post-merger will be subject to SEC reporting shell company business combination rules, including restrictions on certain filings and offerings for up to three years.
• Rallybio's stockholders will experience significant dilution post-merger, with reduced ownership and voting influence in the combined company.
• The company has a small workforce, with only 6 full-time employees as of September 30, 2026, reflecting wind-down activities.
• Rallybio's RLYB116 candidate is designed for subcutaneous administration via autoinjector, potentially improving patient adherence and reducing treatment burden compared to intravenous antibody therapies.
• The company emphasizes manufacturing efficiency for RLYB116, which is expressed in E. coli, potentially lowering production costs compared to mammalian cell culture-based antibodies.